Advances in the pathophysiology of constitutive and inducible cyclooxygenases: two enzymes in the spotlight (Q35035304)

5 August 2017

1 reference

title

Advances in the pathophysiology of constitutive and inducible cyclooxygenases: two enzymes in the spotlight (English)

1 reference

5 August 2017

1 reference

Luca Parente

1

1 reference

PubMed ID

12504791

5 August 2017

Mauro Perretti

series ordinal

2

1 reference

PubMed ID

12504791

5 August 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

5 August 2017

Biochemical Pharmacology

1 reference

5 August 2017

65

1 reference

5 August 2017

2

1 reference

5 August 2017

153-159

1 reference

Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

The coxibs, selective inhibitors of cyclooxygenase-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

7 January 2021

Cyclooxygenases 1 and 2

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Prostaglandins and leukotrienes: advances in eicosanoid biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Distribution and regulation of cyclooxygenase-2 in carrageenan-induced inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Pharmacological analysis of cyclooxygenase-1 in inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Limited anti-inflammatory efficacy of cyclo-oxygenase-2 inhibition in carrageenan-airpouch inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Differential effect of FR122047, a selective cyclo-oxygenase-1 inhibitor, in rat chronic models of arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Inducible cyclooxygenase may have anti-inflammatory properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

The hyperalgesic effects of prostacyclin and prostaglandin E2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Nociception in cyclooxygenase isozyme-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

The analgesic effect profile of FR122047, a selective cyclooxygenase-1 inhibitor, in chemical nociceptive models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

NSAID-induced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Selective COX-2 inhibitors: is the water becoming muddy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Selective cyclo-oxygenase-2 inhibitors aggravate ischaemia-reperfusion injury in the rat stomach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Angiogenesis in rheumatoid arthritis: implications for future therapeutic strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Immunolocalization of cyclooxygenase-2 in the macula densa of human elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Aspirin as an antiplatelet drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

NSAIDS and selective COX-2 inhibitors: competition between gastroprotection and cardioprotection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

ML 3000 reduces gastric prostaglandin synthesis without causing mucosal injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901422-3

10.1016/S0006-2952(02)01422-3

7 January 2021

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

12504791